Summary
Gilead Sciences, Inc. reported significant revenue growth for the fiscal year ended December 31, 2001, reaching $233.8 million. This growth was primarily driven by its antifungal drug, AmBisome, which accounted for 78% of total revenues, generating $181.6 million. The company also saw initial sales from Viread, its HIV treatment, which was approved in the U.S. in October 2001 and the EU in February 2002. A key strategic move was the sale of its oncology assets to OSI Pharmaceuticals in December 2001 for up to $200 million, allowing Gilead to sharpen its focus on infectious diseases. Financially, Gilead remains in an investment phase, reporting a net loss for the year due to substantial research and development expenses, which totaled $185.6 million. The company ended the year with a strong cash position of $582.9 million, indicating healthy liquidity to fund ongoing development and potential future acquisitions. Investors should note the company's reliance on AmBisome and the critical role Viread is expected to play in future revenue generation and its competitive landscape.
Key Highlights
- 1Total revenues grew to $233.8 million in 2001, up from $195.6 million in 2000.
- 2AmBisome remains the primary revenue driver, contributing $181.6 million (78% of total revenue) in 2001.
- 3Viread, a new HIV treatment, achieved initial sales of $15.6 million in 2001 following its U.S. approval in October.
- 4Gilead sold its oncology assets to OSI Pharmaceuticals for up to $200 million, a strategic move to focus on infectious diseases.
- 5Research and Development (R&D) expenses increased to $185.6 million in 2001, reflecting continued investment in pipeline development.
- 6The company ended 2001 with $582.9 million in cash, cash equivalents, and marketable securities, demonstrating strong liquidity.
- 7Gilead reported a net income of $52.3 million in 2001, a significant turnaround from a net loss of $56.8 million in 2000, largely due to the oncology asset sale gain.